2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.
TL;DR
- New GLP-1 pills for obesity from Novo Nordisk and Eli Lilly are poised to significantly impact the booming GLP-1 market.
- Pills offer a more convenient and potentially cheaper alternative to weekly GLP-1 injections, attracting new patient groups.
- The introduction of oral options is expected to expand the overall weight loss and diabetes drug market.
- While injections may offer greater weight loss, pills provide a crucial alternative for needle-averse individuals and those seeking less intensive treatment.
- Analysts forecast that pills could capture a significant portion of the global weight-loss drug market by 2030.
- Pricing for pills is generally lower than injections, especially for cash-paying patients, although insurance coverage for pills is still uncertain.
- Existing injections will likely remain a preferred option for patients needing substantial weight loss or those who prefer a weekly regimen.
- Several other drugmakers are developing their own oral GLP-1 medications, indicating a competitive landscape for future treatments.